发明公开
- 专利标题: PEGYLATED DRUG-LINKERS FOR IMPROVED LIGAND-DRUG CONJUGATE PHARMACOKINETICS
-
申请号: US18740431申请日: 2024-06-11
-
公开(公告)号: US20240325561A1公开(公告)日: 2024-10-03
- 发明人: Robert LYON , Patrick BURKE , Joshua HUNTER
- 申请人: Seagen Inc.
- 申请人地址: US WA Bothell
- 专利权人: Seagen Inc.
- 当前专利权人: Seagen Inc.
- 当前专利权人地址: US WA Bothell
- 分案原申请号: US17378550 2021.07.16
- 主分类号: A61K47/68
- IPC分类号: A61K47/68 ; A61K39/00 ; A61K47/54 ; A61K47/60 ; C07K16/28
摘要:
The present invention provides Ligand-Drug Conjugates comprising a PEG Unit in a parallel orientation to the Drug Unit. The invention provides inter alia, Ligand-Drug Conjugates (LDCs), methods of preparing and using them, and intermediates thereof. The Ligand-Drug Conjugates are stable in circulation, yet capable of inflicting cell death on targeted cells or inhibiting proliferation of targeted cells once its drug cargo is released in the vicinity or within targeted cells. In principle embodiments, an LDC of the present invention is represented by the structure of Formula I.
信息查询
IPC分类: